PUBLISHER: IMARC | PRODUCT CODE: 1451500
PUBLISHER: IMARC | PRODUCT CODE: 1451500
The global tissue engineering market size reached US$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.
Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.
Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global tissue engineering market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.
Synthetic Scaffold Material
Biologically Derived Scaffold Material
Others
Orthopedics and Musculoskeletal
Neurology
Cardiovascular
Skin and Integumentary
Dental
Others
Hospitals and Clinics
Ambulatory Facilities
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.